Literature DB >> 17543152

Antiprothrombin antibodies: a comparative analysis of homemade and commercial methods. A collaborative study by the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA).

A Tincani1, G Morozzi, A Afeltra, C Alessandri, F Allegri, O Bistoni, N Bizzaro, D Caccavo, M Galeazzi, R Gerli, L Giovannelli, G Longobardo, M Lotzniker, F Malacarne, P Migliorini, A Parodi, F Pregnolato, A Radice, V Riccieri, M Ruffelli, R A Sinico, R Tozzoli, D Villalta, R Marcolongo, P Meroni.   

Abstract

OBJECTIVE: Prothrombin (PT) is a target for antibodies with lupus anticoagulant (LA) activity, suggesting the possible application of anti-prothrombin antibody (aPT) assays in patients with antiphospholipid syndrome (APS). Different methods - both homemade and commercial - for the detection of aPT are available, but they seem to produce conflicting results. The purpose of this study was to compare the performance of different assays on a set of well-characterized serum samples. PATIENTS AND METHODS: Sera were gathered from 4 FIRMA institutions, and distributed to 15 participating centres. Forty-five samples were from patients positive for LA and/or anticardiolipin antibodies (aCL) with or without APS, and 15 were from rheumatoid arthritis (RA) patients negative for antiphospholipid antibodies. The samples were evaluated for IgG and IgM antibodies using a homemade direct aPT assay (method 1), a homemade phosphatidylserine-dependent aPT assay (aPS/PT, method 2), and two different commercial kits (methods 3 and 4). In addition, a commercial kit for the detection of IgG-A-M aPT (method 5) was used.
RESULTS: Inter-laboratory results for the 5 methods were not always comparable when different methods were used. Good inter-assay concordance was found for IgG antibodies evaluated using methods 1, 3, and 4 (Cohen k > 0.4), while the IgM results were discordant between assays. In patients with thrombosis and pregnancy losses, method 5 performed better than the others.
CONCLUSION: While aPT and aPS/PT assays could be of interest from a clinical perspective, their routine performance cannot yet be recommended because of problems connected with the reproducibility and interpretation of the results.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17543152

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  4 in total

1.  Assessment of anti-prothrombin antibodies in thrombosis complicating inflammatory bowel diseases.

Authors:  Simone Saibeni; Maria J Etchevers; Dolors Tassies; Julián Panés; Joan C Reverter; Silvio Danese; Josep M Piqué; Savino Bruno; Maurizio Vecchi; Antonio Gasbarrini; Miquel Sans
Journal:  Int J Colorectal Dis       Date:  2013-04-16       Impact factor: 2.571

2.  Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS?

Authors:  Francesca Pregnolato; Cecilia B Chighizola; Susan Encabo; Zakera Shums; Gary L Norman; Armando Tripodi; Veena Chantarangkul; Tiziana Bertero; Valeria De Micheli; Maria Orietta Borghi; Pier Luigi Meroni
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

3.  Detection of antiphosphatidylserine/prothrombin antibodies and their potential diagnostic value.

Authors:  Polona Žigon; Saša Čučnik; Aleš Ambrožič; Tanja Kveder; Snežna Sodin Šemrl; Blaž Rozman; Borut Božič
Journal:  Clin Dev Immunol       Date:  2013-09-26

4.  Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome.

Authors:  Maria Orietta Borghi; Asmaa Beltagy; Emirena Garrafa; Daniele Curreli; Germana Cecchini; Caterina Bodio; Claudia Grossi; Simonetta Blengino; Angela Tincani; Franco Franceschini; Laura Andreoli; Maria Grazia Lazzaroni; Silvia Piantoni; Stefania Masneri; Francesca Crisafulli; Duilio Brugnoni; Maria Lorenza Muiesan; Massimo Salvetti; Gianfranco Parati; Erminio Torresani; Michael Mahler; Francesca Heilbron; Francesca Pregnolato; Martino Pengo; Francesco Tedesco; Nicola Pozzi; Pier Luigi Meroni
Journal:  Front Immunol       Date:  2020-10-15       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.